Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F083 - Red Flags and Emergencies in Dermatology

Saturday, February 17; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Make an initial diagnosis, identify a critical situation, red flags and emergencies.
  • Identify the pathological events and causes of acute life-threatening cutaneous disease.
  • Recognize the urgent and appropriate interventions needed and, be well-informed on new and modern treatments of acute life-threatening cutaneous disease.

Description

It is generally — and erroneously — believed that the field of dermatology does not include life-threatening situations. The truth is that the dermatology unit is no stranger to life-threatening skin diseases, and dermatologists are not spared the possibility of needing to deal with severely sick patients. Indeed, dermatologists are frequently the first physicians to examine the patient, thus becoming responsible for making the initial diagnosis of grave conditions requiring urgent attention. The present session will provide descriptions of a selection of such diseases with the aim of guiding dermatologists in rapid and accurate diagnostic decision-making.

Disclosures

  • Gottlieb, Alice B., MD, PhD: AbbVie – C(H), SP(H); Allergan, Inc – C(H); Beiersdorf, Inc. – A(H); BMS – A(H); Celgene Corporation – A(H); Dermira – C(H); Dr. Reddy – C(H); Eli Lilly and Company – SP(H); Incyte Corporation – C(H), I(Grants/Research Funding); Janssen Biotech – SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – A(H); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Parish, Lawrence C., MD: Actavis – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Derma Sciences Inc. – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Glenmark Generics Inc. – C(H); Novartis – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vitae Pharmaceuticals – I(Grants/Research Funding);
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Shear, Neil H., MD: AbbVie – A(H); Actelion – SP(H); Amgen – A(Grants/Research Funding); Biogen – A(H); Celgene Corporation – SP(H); Eli Lilly and Company – A(H); Janssen-Ortho Inc. – C(H), SP(H); Leo Pharma Inc – C(H); Novartis Pharmaceuticals Corp. – A(H), C(H); Sanofi/Regeneron – A(H); Valeant Pharmaceuticals International – A(H);
  • Wolf, Ronni, MD: no financial relationships exist with commercial interests.
  • Zaenglein, Andrea L., MD: Allergan, Inc – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Cassiopea S.p.A. – C(Fees); Dr. Reddy – C(Fees); Innovaderm Research Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H);
Schedule
Saturday, February 17
3:30 PM
Dr. Wolf / Red flags and emergencies in dermatology: Introduction
3:40 PM
Dr. Rosen / The eschar: Sign of life-threatening disorders
4:10 PM
Dr. Rosen / Q&A
4:15 PM
Dr. Shear / Severe, acute adverse cutaneous drug reactions
4:30 PM
Dr. Shear / Q&A
4:35 PM
Dr. Zaenglein / serious and life-threatening cutaneous conditions in neonates and children
4:50 PM
Dr. Zaenglein / Q&A
4:55 PM
Dr. Gottlieb / Use of biologic agents and chemotherapy in cutaneous emergencies
5:10 PM
Dr. Gottlieb / Q&A
5:15 PM
Dr. Parish / Erythroderma: Diagnosing and treating the "Red Man"
5:25 PM
Dr. Parish / Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 6D
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Ronni Wolf, MD
Speakers
  • Alice B. Gottlieb, MD, PhD, FAAD - Handout
  • Andrea L. Zaenglein, MD, FAAD
  • Lawrence C. Parish, MD, FAAD
  • Neil H. Shear, MD, FAAD
  • Theodore Rosen, MD, FAAD - Handout